At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
Salmon Protein Hydrolysatedietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Proof-of-concept Study to Evaluate the Efficacy of Salmon Protein Hydrolysate Powder on Energy Increase and Anti-inflammatory Modulation in Healthy Males and Females
In Brief
A Phase 1 clinical trial evaluating Salmon Protein Hydrolysate for Healthy. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The objective of this study is to evaluate the efficacy of Salmon Protein Hydrolysate Powder (CollaGo®) on energy increase and anti-inflammatory modulation in healthy males and females. Eligible participants will be asked to consume 1 sachet of CollaGo for 128 days and keep a study diary. Assessments will be measured at the randomization visit, and the end of study visit.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesCanada
CollaboratorsKGK Science Inc.
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedMay 2018
Enrollment StartJun 2018
Primary CompletionOct 2018
TodayJul 2026
First PostedMay 24, 2018
Enrollment StartJun 5, 2018
Primary CompletionOct 23, 2018
TodayJul 1, 2026
Enrollment to primary: 5 monthsPosted 8.1 years ago
Interventions
Salmon Protein Hydrolysatedietary
4g of salmon protein hydrolysate per serving.